O.A. Kadiki, S.E. Moawad, Z.A. Khan, M.R.S. Reddy , A.A. Marzoug
Diabetes Clinic. Benghazi, Libyan Arab Jamahiriya
Garyounis Medical Journal Vol.12, No.1-2. January 1989:32-34
Eighty eight well-controlled insulin-treated diabetics in Benghazi were randomly allocated into three treatment groups during the fasting month of Ramadan. Daily-insulin doses were reduced by about 20%. Group 1 received a mixture of regular and intermediate acting (NPH or Lente) insulins (1:1) at the end of the days fasting (Futur). Group lireceived a mixture of regular and intermediate (1:1) at Futur and a second dose of regular insulin (one fifth the daily dose) at the last meal before the next day’s fast (Suhur). Groupilireceived a mixture of regular and ultralente insulins (1:1) at Futur and a second dose (one fifth daily dose) at Suhur.
Patients in group 1 had significantly better control as compared to groups II and III (P<0. 05). No statistically significent difference could be found between groups II and III. It was concluded that, for well-controlled insulin-treated patients, mixture of regular and intermediate-acting insulins (1:1) at Futur (80% of the daily dose) is the most suitable regimen tested during Ramadan. Keywords: Diabetes Mellitus and Ramadan Link/DOI: